Panic disorder
Major depressive disorder
Agoraphobia
Agranulocytosis, supraventricular tachycardia, hyperaldosteronism, neuroleptic malignant syndrome, akathisia and tardive dyskinesia. Methaemoglobinaemia*

Pharmacology
Pharmacodynamics
Metoclopramide appears to bind to dopamine D2 receptors with nanomolar affinity (Ki = 28.8 nM), where it is a receptor antagonist, and is also a mixed 5-HT3 receptor antagonist/5-HT4 receptor agonist. Mechanism of action
The antiemetic action of metoclopramide is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone  in the central nervous system — this action prevents nausea and vomiting triggered by most stimuli. At higher doses, 5-HT3 antagonist activity may also contribute to the antiemetic effect.The gastroprokinetic activity of metoclopramide is mediated by muscarinic activity, D2 receptor antagonist activity, and 5-HT4 receptor agonist activity. The gastroprokinetic effect itself may also contribute to the antiemetic effect. Metoclopramide also increases the tone of the lower esophageal sphincter.Metoclopramide might influence on mood because of its blockade action on 5-HT4 and 5-HT3. Chemistry
Metoclopramide is a substituted benzamide; cisapride and mosapride are structurally related. History
Metoclopramide was first described by Louis Justin-Besançon and Charles Laville in 1964, while working to improve the anti-dysrhythmic properties of procainamide. That research project also produced the product sulpiride. The first clinical trials were published by Tourneu et al. in 1964 and by Boisson and Albot in 1966. Justin-Besançon and Laville worked for Laboratoires Delagrange and that company introduced the drug as Primperan in 1964. Laboratoires Delagrange was acquired by Synthelabo in 1991 which eventually became part of Sanofi.A.H.
It is also used in pregnancy as a second choice for treatment of hyperemesis gravidarum (severe nausea and vomiting of pregnancy).It is also used preventatively by some EMS providers when transporting people who are conscious and spinally immobilized. Migraine
In migraine headaches, metoclopramide may be used in combination with paracetamol (acetaminophen) or in combination with aspirin. Gastroparesis
Evidence also supports its use for gastroparesis, a condition that causes the stomach to empty poorly, and as of 2010 it was the only drug approved by the FDA for that condition.It is also used in gastroesophageal reflux disease. Lactation
While metoclopramide is used to try to increase breast milk production, evidence for its effectiveness for this is poor. Its safety for this use is also unclear. Procedures
Intravenous metoclopramide is used in small-bowel follow-through, small-bowel enema, and radionuclide gastric-emptying studies to reduce the time taken for barium to go through the intestines, thus reducing the total time needed for the procedures. Metoclopramide also prevents vomiting after oral ingestion of barium. Contraindications
Metoclopramide is contraindicated in pheochromocytoma. It should be used with caution in Parkinsons disease since, as a dopamine antagonist, it may worsen symptoms. Long-term use should be avoided in people with clinical depression, as it may worsen ones mental state.